Bill Meury, Anthos Therapeutics CEO
April 22, 2024 03:48 PM EDT
People
Pharma

Weeks af­ter clos­ing Bris­tol My­ers deal, Karuna's ex-CEO heads to Black­stone-backed An­thos

Nicole DeFeudis

Editor

How does Bill Meury cel­e­brate a $14 bil­lion merg­er? With a new post at a Black­stone-found­ed biotech.

Meury has been ap­point­ed CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times